China Volume-Based Procurement (VBP) for Medical Devices: Price Cuts & Strategy
Guide to China's NHSA volume-based procurement (VBP) for medical devices: round history, price cuts, provincial alliances, and multinational strategy.
Executive Summary & Direct Answer
Scenario Question: Our high-value medical device or IVD diagnostic is NMPA-registered in China, and China's National Healthcare Security Administration (NHSA) has announced a centralized volume-based procurement (VBP) round for our product category. Should our company bid, what price reductions should we expect, and what are the strategic consequences if we decline to participate?
Direct Answer: China's Volume-Based Procurement (VBP) for medical devices—known locally as Jizhong Caigou (集中采购) or Ji Cai (集采)—has fundamentally reshaped the world's second-largest medtech market. Overseen by the National Healthcare Security Administration (NHSA) and executed via the Joint Procurement Organization (JPO) and provincial bidding alliances, VBP exchanges guaranteed hospital purchasing volumes (typically 70% to 80% of total public hospital demand) for drastic price reductions.
As of July 2026, six national batches have been completed, covering 9 major categories and 142 varieties of high-value consumables. Average price cuts run from roughly 50% to 93%:
- Batch 1 — Coronary Stents (bid November 5, 2020): Average 93% price cut, reducing average stent prices from roughly 13,000 RMB (
$1,900 USD) to approximately 700 RMB ($108 USD). - Batch 2 — Artificial Joints (September 2021): Average 82% price cut, lowering total hip and knee replacement construct costs from over 30,000 RMB to between 5,000 RMB and 7,000 RMB.
- Batch 3 — Spinal Implants (September 2022): Average 84% price cut across cervical, thoracolumbar, and fusion systems.
- Batch 4 — IOLs & Sports Medicine (October–November 2023): Average ~70% price cut.
- Batch 5 — Cochlear Implants & Peripheral Vascular Stents (bid December 19, 2024): Cochlear implant sets fell from an average of over 200,000 RMB to about 50,000 RMB (over 75%); peripheral vascular stents from over 20,000 RMB to about 3,000 RMB (over 80%).
- Batch 6 — Drug-Coated Balloons & Urological Interventional (results published January 14, 2026): 12 product types across two categories; 202 of 227 bidding companies won. This round introduced an explicit "anti-involution" (反内卷) floor: when the lowest bid is abnormally low, the price-gap benchmark becomes 65% of the shortlisted average rather than the single lowest price.
- Inter-Provincial Alliance Tenders: Regional alliances led by Henan (orthopedic trauma), Fujian (cardiac electrophysiology), Anhui (IVD reagents), Sichuan (dental implants), and others extend coverage far beyond the national batches, with average cuts ranging from roughly 47% to 89% depending on category.
┌─────────────────────────────────────────────────────────────────────────┐
│ China Medical Device Pricing Reality │
└────────────────────────────────────┬────────────────────────────────────┘
│
┌───────────────────────┴───────────────────────┐
▼ ▼
┌──────────────────────────┐ ┌──────────────────────────┐
│ Tendered Segment │ │ Off-Tender Segment │
│ (VBP Winner Volume) │ │ (Premium / Non-VBP) │
├──────────────────────────┤ ├──────────────────────────┤
│ - 70-80% Public Hospital │ │ - 20-30% Public Residual │
│ Allocated Volume │ │ + Private Hospitals │
│ - 70-93% Price Cut │ │ - Premium Next-Gen Tech │
│ - Low-Margin Commodity │ │ - Higher Margin / Out-of-│
│ - Low CSO Commission │ │ Pocket / Innovation │
└──────────────────────────┘ └──────────────────────────┘
The decision to bid is a stark commercial tradeoff. Winning a VBP tender secures large committed public hospital volume, but roughly halves absolute gross profit per unit and dismantles traditional distributor compensation models. Sitting out or losing a tender risks losing access to 70%+ of public hospital procurement in participating provinces, and that lost share is hard to win back: in the coronary stent category, non-winning brands were largely absent from the public-hospital channel for the entire first contract cycle, and the 2022 renewal was structured to retain winning suppliers rather than re-open the field to them.
Two developments since 2024 materially change this calculus and are not yet reflected in most published guidance: renewal rounds stabilise prices rather than cutting them again, and NHSA now prices innovation explicitly through comparison coefficients instead of forcing all products in a group to one price. Both are covered in detail below.
Multinational corporations (MNCs) navigating China must coordinate VBP strategy with their broader China NMPA medical device registration timelines, align tender bidding with global medical device go-to-market strategy, and benchmark local pricing against global frameworks in our medical device reimbursement guide.
What is China's volume-based procurement and who runs it?
China's Volume-Based Procurement (VBP) policy was established to curb escalating healthcare expenditures, eliminate inflated distributor markups, and dismantle illicit kickback channels in public hospital procurement.
Legislative & Regulatory Foundations
Following the establishment of the National Healthcare Security Administration (NHSA) in 2018, China centralized purchasing authority over pharmaceuticals and medical devices under the State Council's healthcare reform directives.
┌─────────────────────────────────────────────────────────────────────────┐
│ China VBP Governance & Execution Structure │
└────────────────────────────────────┬────────────────────────────────────┘
│
▼
┌─────────────────────────────────────┐
│ NHSA (National Healthcare │
│ Security Administration) │
└──────────────────┬──────────────────┘
│
┌───────────────────────┴───────────────────────┐
▼ ▼
┌──────────────────────────┐ ┌──────────────────────────┐
│ National JPO (Tianjin) │ │ Inter-Provincial Alliance│
│ (High-Value Consumables)│ │ (Lead-Province Model) │
├──────────────────────────┤ ├──────────────────────────┤
│ - Coronary Stents │ │ - Henan: Ortho Trauma │
│ - Artificial Joints │ │ - Fujian: Electrophys. │
│ - Spinal Implants │ │ - Anhui: IVD Reagents │
│ - IOLs / Sports Medicine │ │ - Sichuan: Dental Implant│
│ - Cochlear / Periph.Stent│ │ - Guangdong: Ultra. Scalp│
│ - Drug-Coated Balloons │ │ - Shaanxi: IOL (early) │
└──────────────────────────┘ └──────────────────────────┘
VBP operates through two primary administrative mechanisms:
- National Joint Procurement Organization (JPO / 国家组织高值医用耗材联合采购办公室): Headquartered in Tianjin, the National JPO selects broad, high-volume, high-value medical consumable categories and conducts centralized nationwide tenders.
- Inter-Provincial Bidding Alliances (跨省联盟采购): Coalitions led by a designated lead provincial healthcare security bureau (Henan, Fujian, Anhui, Sichuan, Guangdong, Hunan, Guangxi and others) aggregate volume across anywhere from a handful of provinces to all 31 mainland provincial-level regions plus the Xinjiang Production and Construction Corps, negotiating prices for specialised consumables and diagnostic reagents not yet covered by national batches. NHSA assigns lead provinces by category each year, so the alliance map changes annually.
Core Mechanics of VBP Bidding
VBP differs fundamentally from traditional hospital-level tendering through four core mechanisms:
- Volume Guarantee (带量采购): Participating public hospitals submit explicit, legally binding annual procurement volume commitments (typically 70% to 80% of historical consumption).
- Group Categorization & Bidding Tiers (分组竞价): Bidding products are split into Quality/Brand Groups (Group A for high-market-share/NMPA-imported/top-tier brands; Group B for domestic/emerging brands) to ensure clinical continuity while encouraging price competition.
- Maximum Price Ceilings & Elimination Rates (限价与淘汰率): NHSA establishes strict maximum allowable bidding ceilings. Tenders enforce target elimination rules (e.g., the bottom 20-30% highest-bidding companies in a group are automatically disqualified).
- Direct Settlement & Payment Guarantees (医保直接结算): Medical insurance funds directly pay winning suppliers or enforce strict hospital payment windows (usually 30 days), eliminating legacy hospital accounts receivable delays of 12 to 18 months.
What is the round-by-round price-cut history (stents, joints, spine, and beyond)?
The rollout of national medical device VBP has progressed through distinct category batches, expanding from cardiovascular hardware into orthopedics and IVD diagnostics.
NATIONAL VBP ROUND PRICE CUT TIMELINE
Nov 2020 Stents [=================== 93%]
Sep 2021 Hip & Knee Joints [================ 82%]
Sep 2022 Spinal Implants [================= 84%]
Oct 2023 IOLs / Sports Med [============== ~70%]
Dec 2024 Cochlear / Periph [=============== >75-80%]
Jan 2026 DCB / Urological [ anti-involution floor rules ]
Complete National VBP Batch Summary
| Batch Round | Bid / Result Date | Product Category | Scope & Key Bidders | Average Price Cut | Historical vs. Winning Price Range |
|---|---|---|---|---|---|
| National Batch 1 | Bid November 5, 2020 (Tianjin) | Drug-Eluting Coronary Stents | Cobalt-chromium & stainless steel drug-eluting coronary stents (Medtronic, Boston Scientific, MicroPort, Lepu, SinoMed) | 93% | Decreased from ~13,000 RMB to an average of ~700 RMB (~$108 USD) per stent. |
| National Batch 2 | September 2021 | Artificial Joint Replacements | Primary total hip constructs (ceramic-ceramic, ceramic-polyethylene) & total knee constructs (Zimmer Biomet, Stryker, DePuy Synthes, Chunli) | 82% | Decreased from >30,000 RMB to 5,000–7,000 RMB per total joint construct. |
| National Batch 3 | September 2022 | Orthopedic Spinal Implants | Cervical/lumbar fixation, interbody fusion cages, and thoracolumbar systems (Medtronic, Johnson & Johnson, Weigao) | 84% (USTR); 80% per some analyst tables | Fixation sets dropped from tens of thousands of RMB to the low thousands. |
| National Batch 4 | October–November 2023 | Intraocular Lenses (IOLs) & Sports Medicine | Monofocal/multifocal IOLs, arthroscopic anchors, suture passers, and ligament reconstruction constructs (Alcon, J&J Vision, Smith & Nephew) | about 70% | Premium IOL and sports-medicine constructs fell into the low-thousands RMB range. |
| National Batch 5 | Bid December 19, 2024 (Tianjin) | Cochlear Implants & Peripheral Vascular Stents | Cochlear: MED-EL, Advanced Bionics, Cochlear, Nurotron, Listent. Peripheral stents: Cordis, Covidien, Abbott, Boston Scientific, Bard, Biotronik, MicroPort | Cochlear >75%; peripheral stents >80% | Cochlear sets (implant + processor) from >200,000 RMB to ~50,000 RMB; peripheral stents from >20,000 RMB to ~3,000 RMB. 23 of 24 companies won (96%). |
| National Batch 6 | Results published January 14, 2026 | Drug-Coated Balloons & Urological Interventional | 12 product types; DCB — all 32 bidding companies won (42 products). Urological — 170 of 195 companies won (398 products) | Not published as a single headline average | Pre-VBP category market ~11 billion RMB. Introduced the 65%-of-shortlisted-average price-gap benchmark (triggered in 8 of 20 competition groups). |
Renewal Rounds: Prices Stabilise, They Do Not Keep Collapsing
A widespread misconception is that each renewal (接续采购) delivers another 60–80% cut. It does not. Once a category has been through its first national batch, renewals are explicitly designed for price stability:
| Renewal | Date | Outcome |
|---|---|---|
| Coronary stents, 1st renewal | Bid November 29, 2022 (Changzhou) | 10 companies / 14 products won (91% win rate); ~1.78 million stents; average winning price ~770 RMB, terminal price band 730–848 RMB — above the 2020 average of ~700 RMB. 3-year cycle from January 2023. |
| Artificial joints, renewal | Bid May 21, 2024 (Tianjin) | 6,281 hospitals, 581,600 sets (+7.42% vs first round); average price down only ~6%; hip average 7,000 → 6,600 RMB, knee average 5,000 → 4,700 RMB; 54 companies / 167 products won. |
| Coronary stents, 2nd renewal | In progress, 2026 | Demand reporting reopened April 2026; results being executed in provinces from mid-2026. |
Planning implication: model the first national batch in a category as the cliff event and subsequent renewals as a plateau with single-digit erosion. Companies that assumed a second 80% cut at renewal have systematically under-invested in categories that were, in fact, price-stable.
Detailed Teardown of Major Batches
1. National Coronary Stent Procurement (Batch 1)
In November 2020, Tianjin hosted China's inaugural national device tender. Covering drug-eluting coronary stents, the tender aggregated 1.07 million stents—representing 80% of national public hospital demand. Ten products won bids. Medtronic's Resolute Integrity stent dropped from roughly 15,000 RMB to 648 RMB, while Boston Scientific's Promus PREMIER dropped from 13,000 RMB to 776 RMB. Domestic winners (MicroPort, Lepu, SinoMed) accepted similar pricing. The tender established the precedent that VBP converts high-margin specialty hardware into low-margin volume commodities.
2. National Artificial Joint Procurement (Batch 2)
In September 2021, NHSA targeted orthopedic hip and knee implants. Recognizing material variations (e.g., ceramic-on-ceramic vs. ceramic-on-polyethylene hip joints), NHSA implemented product grouping. While international players like Zimmer Biomet, DePuy Synthes (J&J), and Stryker won portions of the tender, average price cuts reached 82%. Post-tender averages settled at roughly 7,000 RMB per hip construct and 5,000 RMB per knee construct — figures independently confirmed by the 2024 renewal round, which reported hip and knee averages of 7,000 and 5,000 RMB respectively as its own pre-renewal baseline.
3. National Spinal Implant Procurement (Batch 3)
The September 2022 tender covered orthopedic spinal consumables — cervical and thoracolumbar fixation, interbody fusion, and related systems — grouped into product-system categories rather than individual SKUs, because a single spinal case consumes a case-specific combination of screws, rods, cages and connectors. Spine constructs historically carried some of the highest gross margins in Chinese orthopedics. The USTR's 2023 China WTO Compliance Report records an average price cut of 84% for this round; some analyst tables report 80%. Either figure moved fixation systems from tens of thousands of RMB into the low thousands, compressing third-party orthopedic distributor margins to near zero.
With Batch 3, NHSA completed what it describes as block coverage of the two categories where Chinese device prices were most inflated: cardiology and orthopedics.
4. Cochlear Implants and Peripheral Vascular Stents (Batch 5)
Batch 5, opened in Tianjin on December 19, 2024, is the round most worth studying for multinationals, because foreign firms did not sit it out — they led it. Head foreign brands took first place in all four competition groups (cochlear implants plus three peripheral-stent groups), and 23 of the 24 participating companies won something.
The economics explain why. Cochlear implants and peripheral vascular stents were low-penetration, growth markets rather than mature ones: China performs roughly 1.2 million cardiac stent procedures a year but only 200,000–300,000 peripheral vascular stent implants, and demand in this round was just 11,000 cochlear sets and 258,000 peripheral stents. Cutting a set from over 200,000 RMB to about 50,000 RMB expands the addressable patient population rather than merely redistributing an existing one.
Batch 5 also priced innovation explicitly. Cochlear implant bodies were assigned comparison coefficients by capability — 1 : 1.2 : 1.3 for no-MRI, 1.5T-compatible, and 3.0T-compatible implants respectively — so a more capable device was permitted a proportionally higher winning price rather than being forced to match the cheapest product in the group. This is the single most important mechanical development for premium manufacturers, and it carried into Batch 6.
How do national NHSA tenders differ from inter-provincial alliance tenders?
While National JPO tenders capture headline-grabbing categories, inter-provincial alliance tenders cover a far wider spectrum of medical devices and IVD diagnostic reagents.
Structural Comparison: National vs. Provincial Alliance VBP
| Feature / Dimension | National NHSA JPO Tenders | Inter-Provincial Alliance Tenders |
|---|---|---|
| Lead Authority | National Healthcare Security Administration (Tianjin JPO) | NHSA-designated lead provincial bureau (Henan, Fujian, Anhui, Sichuan, Guangdong, Hunan, Guangxi…) |
| Geographic Scope | All 31 mainland provincial-level regions plus the Xinjiang Production and Construction Corps | Varies by category: from ~10 members to all 31 regions plus the Corps |
| Target Categories | High-volume, highly standardized high-value consumables (stents, joints, spine, IOLs, cochlear, peripheral stents, drug-coated balloons) | Specialised consumables, IVD reagents, electrophysiology, orthopedic trauma, dental implants, TCM needles |
| Volume Aggregation | 70% to 80% of total national public hospital volume (95% in the 2022 stent renewal) | Typically 70%–90% of reported participating-hospital volume |
| Average Price Reduction | ~70% to 93% in first-time rounds; single-digit in renewals | ~47% to 89%, widest spread of the two mechanisms |
| Bidding Frequency | Roughly one to two new batches per year; 2–3 year contract cycles | Ongoing rolling category tenders, lead province reassigned annually |
| Where the volume actually is | 6 batches, 9 categories, 142 varieties since 2020 | The large majority of tendering activity by category count |
The IVD Reagent Frontier: The Anhui & Guangdong Alliance Precedents
In Vitro Diagnostics (IVD) was long considered resistant to centralized VBP due to closed-system instrument-reagent lock-in (where reagent formulations are proprietary to specific instrument platforms). However, provincial alliances developed novel tendering frameworks to bypass closed-system constraints.
┌─────────────────────────────────────────────────────────────────────────┐
│ IVD Alliance VBP Mechanism (Anhui Model) │
├─────────────────────────────────────────────────────────────────────────┤
│ 1. Unbundle Reagent Pricing from Instrument Placement Contracts. │
│ 2. Aggregate Public Lab Test Volume across Chemiluminescence Assays │
│ (Tumor Markers, Thyroid Function, Infectious Disease, Myocardial). │
│ 3. Enforce 30-50% Price Reductions on Reagent Packs. │
│ 4. Require Instrument Manufacturers to Adapt or Supply Reagents at │
│ Tendered Unit Rates for Installed Base. │
└─────────────────────────────────────────────────────────────────────────┘
- The Anhui provincial pilot (2021) — proof that closed systems can be tendered. Anhui published its chemiluminescence procurement document on August 9, 2021, produced results on November 2, and began execution on November 11. It covered 23 reagent projects across five clinical groups: tumour markers, thyroid function, infectious disease, cardiac markers, and procalcitonin. Crucially, Anhui tendered reagents only and explicitly excluded the instruments, which is what broke the closed-system defence. Average price cut: about 47%, with 12 companies winning. Roche, Beckman Coulter, Sysmex and Autobio declined to bid and were moved to a monitored filing catalogue — and lost share as a result. Domestic chemiluminescence makers led by Mindray, Snibe (New Industries) and YHLO expanded their installed bases sharply, a well-documented redistribution of the Anhui chemiluminescence market toward domestic platforms once the multinational reagent lock-in was broken.
- The Anhui-led 25-province alliance (2023–2024) — the multinationals came back. Anhui was designated national lead for IVD by NHSA, and the resulting 25-province (including autonomous regions and the Xinjiang Corps) alliance published results in December 2023 covering HPV-DNA, HCG, sex hormone six-panel, infectious disease eight-panel, and glucose metabolism two-panel testing. 120 companies won at an average cut of 53.9%, maximum 73%, with estimated annual savings near 6 billion RMB. This time Roche, Abbott, Beckman and Siemens all bid and all won, at declared reductions above 50%. One mainstream imported infectious-disease eight-panel went from a weighted average of 17.14 RMB per test to 6.59 RMB (−57.9%).
- The Anhui-led 28-province alliance (2024–2026) — scope keeps widening. Tumour markers (16 assays) and thyroid function (9 assays), with 11,800 medical institutions participating. Average cut 52.62%, maximum 84.25%, projected annual savings above 10 billion RMB, executing across provinces during 2026.
The pattern for IVD is now clear and stable: first-round provincial pilots cut roughly 40–47%; national inter-provincial alliance rounds cut roughly 52–54%. IVD is not experiencing the 80–90% collapses seen in orthopedics, and the trajectory is flat rather than deepening.
Which device categories are now covered, and how is the scope expanding?
VBP has expanded from high-value medical consumables (Gao Zhi Hao Cai) into low-value consumables, IVD reagents, and electrophysiology.
VBP CATEGORY SCOPE MATRIX
│
┌─────────────────────────────────┼─────────────────────────────────┐
▼ ▼ ▼
┌──────────────────┐ ┌──────────────────┐ ┌──────────────────┐
│ High-Value │ │ In Vitro │ │ Low-Value & │
│ Consumables │ │ Diagnostics │ │ Equipment │
├──────────────────┤ ├──────────────────┤ ├──────────────────┤
│ - Coronary Stents│ │ - Chemiluminescence│ │ - Syringes & IV │
│ - Hip/Knee Joints│ │ - Tumor Markers │ │ Tubing │
│ - Spine Implants │ │ - Thyroid Panels │ │ - Dialysis Lines │
│ - IOL Lenses │ │ - Molecular PCR │ │ - Basic Sutures │
│ - Trauma Plates │ │ - HBV/HCV Panels │ │ - Surgical Gloves│
└──────────────────┘ └──────────────────┘ └──────────────────┘
Comprehensive Covered Category Inventory
- Cardiovascular & Interventional: Coronary drug-eluting stents (national Batch 1), drug-coated balloons (national Batch 6), peripheral vascular stents (national Batch 5), electrophysiology diagnostic/therapeutic/cryoablation catheters and transseptal sheaths (Fujian 27-region alliance), coronary cutting balloons (Henan alliance), neurointerventional coils and flow diverters (Beijing-Tianjin-Hebei "3+N" alliance), structural heart occluders (Fujian alliance).
- Orthopedics & Trauma: Total hip and total knee systems (Batch 2), spinal fixation and fusion constructs (Batch 3), sports medicine anchors and ligament constructs (Batch 4), trauma plates, screws and intramedullary nails (Henan 12-region alliance).
- Ophthalmology: Monofocal and premium multifocal/toric intraocular lenses (Batch 4, and earlier the Shaanxi-led inter-provincial alliance).
- ENT & Neurotology: Cochlear implant systems including implant body and speech processor (Batch 5).
- Urology: Ureteral access sheaths, stone-retrieval and related interventional consumables (Batch 6).
- Dental: Titanium and zirconia dental implant systems (Sichuan-led national procurement, plus a capped implantation service fee).
- In Vitro Diagnostics (IVD): Chemiluminescence immunoassay reagents — tumour markers, thyroid function, infectious disease, cardiac markers, procalcitonin, sex hormones, glucose metabolism — plus HPV-DNA molecular assays and biochemistry panels (Anhui-led 25- and 28-region alliances; Jiangxi-led biochemistry alliance).
- General Surgery & Other: Endoscopic and open staplers, ultrasonic scalpel heads, vascular tissue ligation clips, breast biopsy rotational-cutting needles, high-frequency electrosurgical units and neutral electrodes, TCM acupuncture needles, sutures, hemodialysis consumables, medical imaging film.
Regional Provincial Alliance Breakdown & Financial Case Studies
To understand the full reach of VBP beyond national batches, medtech teams must track major regional procurement coalitions:
Henan-led 12-region orthopedic trauma alliance (results July 20, 2021, Luoyang). Henan led Shanxi, Jiangxi, Hubei, Chongqing, Guizhou, Yunnan, Guangxi, Ningxia, Qinghai, Hunan and Hebei. This is the deepest cut in Chinese device VBP history: an average reduction of 88.65% — steeper than the national coronary stent round. 101 companies registered, 89 bid, and 71 companies had 20,751 products selected against a reported demand of ~970,000 sets. Sub-category detail:
- Standard bone plate systems: 4,683 → 606 RMB (−87.05%)
- Locking / multi-axial compression plate systems: 9,360 → 987 RMB (−89.45%)
- Intramedullary nail systems: 11,687 → 1,271 RMB (−89.12%)
The alliance covered roughly 560 million people (~40% of China's population) and was projected to cut annual alliance-region trauma consumable spend from 8.437 billion RMB to 854 million RMB. Trauma hardware is highly fragmented — nearly 7 million SKUs, over half of all medical consumable SKUs in China — which is precisely why aggregation produced such extreme leverage.
Fujian-led cardiac electrophysiology alliance (document October 14, 2022; results January 2023). The largest alliance by membership at the time: Fujian plus 26 other provincial-level regions including the Xinjiang Corps — 27 members in total. It covered essentially every high-unit-price electrophysiology consumable: transseptal sheaths and needles, EP catheter sheaths, irrigation tubing, surface reference electrodes, electro- and magnetic-navigation diagnostic and therapeutic catheters, intracardiac ultrasound catheters, and cryoablation catheters. Average winning-product reduction: 49.35% — deliberately moderate, because this was the first large-scale cardiovascular-adjacent tender and NHSA priced it to keep supply stable. A companion Fujian-led endoscopic stapler alliance averaged 55.52%. The electrophysiology alliance entered its renewal data-collection cycle in July 2026.
Sichuan-led national dental implant procurement (2022–2023). Organised by the Sichuan provincial bidding centre under the State Council's High-Value Medical Consumables Joint Procurement Office, this was nationwide in reach rather than a sub-national alliance. Winning implant system prices fell an average of 55%, to just over 900 RMB, and — uniquely — NHSA paired the device tender with a service-fee cap: public hospitals may not charge more than 4,500 RMB per implant for the implantation procedure itself. Results took effect in April 2023.
Recent and ongoing alliances (2024–2026). Guangdong-led ultrasonic scalpel heads; Zhejiang-led breast biopsy rotational-cutting needles (national); Fujian-led vascular tissue ligation clips (national); Jiangxi-led biochemistry IVD reagents; Henan-led coronary cutting balloons; Hebei-led vascular interventional consumables; Guangxi-led TCM needles across 25 regions plus the Corps (average 51%); Hunan-led high-frequency electrosurgical units and neutral electrodes across 29 regions plus the Corps (184 bidders, ~3.5 billion RMB market, ~80% win rate, April 2026).
The strategic read: alliance tenders, not national batches, are where most category-level exposure now originates. A multinational tracking only the national JPO calendar will be blindsided — orthopedic trauma, electrophysiology, dental, and IVD were all repriced through the alliance channel, and the deepest single cut on record (88.65%) came from an alliance, not a national batch.
Financial Restructuring Case Study: MNC Local P&L Impact
Consider a European orthopedic implant manufacturer selling total hip constructs in China prior to VBP:
- Pre-VBP Unit Economics: Public Hospital Purchase Price = 32,000 RMB (
$4,600 USD). Manufacturer Net Revenue (to distributor) = 12,000 RMB ($1,700 USD). Gross Margin = 85% (COGS = 1,800 RMB). - Post-VBP Unit Economics: Winning Tender Price = 6,800 RMB (~$970 USD). Manufacturer Direct Price = 6,800 RMB. COGS = 1,800 RMB. Manufacturer Gross Margin = 73.5% — on a drastically reduced revenue base (5,000 RMB gross profit per unit vs. 10,200 RMB pre-VBP, a 51% collapse in absolute gross profit per implant).
- The trap in reading that number: the percentage gross margin barely moves (85% → 73.5%), which is why VBP impact is routinely under-forecast in headquarters models. The damage is at the operating line. Volume must roughly double just to hold gross profit flat, while field force, regulatory, warehousing and quality costs are fixed in the short run. A category running a 30% operating margin pre-VBP can go operating-loss-making at unchanged headcount even though gross margin still reads above 70%.
- Commercial Field Restructuring: To restore operating profitability, the manufacturer eliminated 60% of its direct sales representative headcount in tier-1 cities, transitioned hospital servicing to third-party CSOs on a 7% fixed fee structure, and closed regional sub-warehouses in favor of centralized 3PL distribution hubs.
This case study is a MedDeviceGuide illustrative model built from publicly reported tender prices, not the disclosed accounts of a specific company. Treat the structure as transferable and the figures as indicative.
NHSA vs NMPA Coding Alignment: The Medical Consumables Matrix
A critical operational challenge for medical device manufacturers in China is navigating the alignment between NMPA Product Registration Certificates and NHSA Medical Insurance Consumable Coding (医保耗材编码).
┌─────────────────────────────────────────────────────────────────────────┐
│ China Regulatory vs. Procurement Code Matrix │
├────────────────────────────────────┬────────────────────────────────────┤
│ NMPA Registration Certificate │ NHSA Medical Insurance Consumable │
│ (国家药监局医疗器械注册证) │ Code (国家医保局 27 位耗材编码) │
├────────────────────────────────────┼────────────────────────────────────┤
│ - Authorizes market entry │ - Authorizes hospital procurement │
│ - Governed by safety & performance │ & insurance reimbursement │
│ - Valid for 5 years │ - Groups products into VBP tender │
│ - Product classification (Class II/III)│ categories (27-digit code) │
└────────────────────────────────────┴────────────────────────────────────┘
The NHSA coding rule (医保发〔2019〕39号, June 2019) originally defined a 20-character consumable code in five parts. NHSA later extended it to 27 characters by appending a 7-digit serial number that pins down the individual specification and model; the maintenance database no longer accepts 20-character codes. The current structure is:
| Positions | Part | Content |
|---|---|---|
| 1 | Consumable identifier (耗材标识码) | The single uppercase letter C |
| 2–7 | Classification code (分类码) | Six digits encoding discipline, use, anatomic site and function, read as three 2-digit tiers: first-level, second-level, third-level category |
| 8–10 | Generic name code (通用名码) | Three digits for the nationally unified NHSA generic name |
| 11–15 | Product feature code (产品特征码) | Five digits for material and specification characteristics (e.g. nickel-titanium vs. cobalt-chromium) |
| 16–20 | Manufacturer code (生产企业码) | Five digits assigned per NMPA registration certificate or filing record |
| 21–27 | Serial number (流水号) | Seven digits uniquely identifying one specification/model |
Worked example — C0101010010100104937, the 20-character base of a stent product: C identifier; 01 non-vascular interventional therapy materials; 01 respiratory interventional; 01 tracheal/bronchial stent; 001 generic name "stent"; 01001 nickel-titanium alloy; 04937 the manufacturer.
The taxonomy currently spans 17 first-level categories, 174 second-level, 1,046 third-level, and 8,962 material/specification classes. NHSA has been progressively re-cutting it — in 2025 it republished classifications and generic names for seven categories (vascular interventional stents, vascular interventional balloons, staplers and accessories, artificial organs/tissues and supporting materials, non-vascular interventional stents, non-vascular interventional balloons, and implantable cardiac rhythm management devices), and has said orthopedic implant coding is complete and awaiting release.
Why this matters commercially: when NHSA opens a VBP round, it defines eligibility by naming NHSA code segments, not product names. The Fujian electrophysiology alliance, for example, scoped its tender to products under code segments beginning C0201, and its 2026 renewal reporting notice simply told hospitals to report anything whose first five characters are C0201. Your tender exposure is therefore a coding question decided before the tender is announced. Two practical consequences:
- Audit which NHSA code segment each of your registered SKUs sits in now. That segment, not your marketing category, determines which future round captures you.
- A genuinely distinct clinical mechanism can justify a separate generic name and classification, which is the legitimate route to a separate bidding group — but it is decided by NHSA's coding process, and a re-cut like the 2025 seven-category revision can move you without any action on your part.
Public Hospital Procurement Quota Mechanics & Compliance Audit
Public tertiary hospitals (Class 3A / 三甲医院) in China operate under strict NHSA compliance audits regarding VBP execution:
- Target Volume Fulfillment Rate (约定采购量完成率): Hospitals must fulfill at least 80% of their annual VBP winning product volume quota before they are permitted to purchase non-winning or premium alternative devices.
- Institutional Performance Assessment (绩效考核): Provincial implementation notices require that each hospital's execution of VBP results be folded into public-hospital assessment and into the performance review of designated medical insurance institutions, with results linked to the hospital's share of retained VBP savings and to its medical insurance budget allocation for the following year. Hospitals in turn cascade that pressure to departments and individual prescribers through internal controls, so the practical constraint on a surgeon is set by hospital policy rather than by a national rule.
- Medical Insurance Fund Prepayment (医保基金预付与结算): Once a hospital and winning supplier sign the online purchase agreement, the local medical insurance agency must prepay the hospital no less than 30% of the annual agreed purchase amount, and the hospital must settle the supplier no later than the end of the month following goods acceptance. Provinces are also being pushed toward direct medical-insurance-fund-to-manufacturer settlement, which removes hospital receivables risk entirely for winning bidders — historically one of the largest hidden costs of selling into Chinese public hospitals.
Hospital Procurement Committee Audit Protocols & Penalty Mechanisms
Healthcare Security Bureau inspectors perform unannounced annual audits of hospital electronic procurement systems to verify compliance with national and alliance VBP quotas. If an auditing team discovers that a clinical department has deliberately diverted procurement volume away from winning VBP suppliers in order to purchase higher-cost non-tendered imported devices, the hospital faces administrative sanctions.
These penalties include the immediate clawback of pre-funded medical insurance funds, reduction of the hospital's overall annual medical insurance reimbursement budget allocation, and formal administrative reprimands for hospital leadership. Consequently, hospital presidents and procurement committee directors enforce strict internal software controls within hospital Information Systems (HIS) to block non-winning product order entries once the 20% non-tendered volume threshold has been reached.
Furthermore, domestic distributor networks that previously provided indirect clinical support fees to hospital departments are subjected to joint audits by the State Administration for Market Regulation (SAMR) and NHSA. This rigorous enforcement environment has effectively dismantled legacy multi-tiered distributor markup channels across all 31 mainland provinces.
How should a multinational manufacturer decide whether to bid?
For multinational medtech executives, VBP tender submission is an existential commercial decision. Bidding guarantees volume at crushed margins; refusing to bid risks immediate exclusion from China's public hospital system.
Multinational Go / No-Go Bidding Framework
DECISION MATRIX: SHOULD YOU BID?
│
┌───────────────────────┴───────────────────────┐
▼ ▼
Is China >15% of global category? Is China <5% of global revenue?
Is local manufacturing established? Is global price protection critical?
│ │
▼ ▼
BID & DEFEND VOLUME ABSTAIN & PIVOT
- Submit competitive Group A bid. - Protect global reference price.
- Restructure local CSO sales model. - Focus on private hospital channel.
- Accelerate localized production. - Launch next-gen premium product.
Quantitative Decision Matrix
| Strategic Factor | Scenario A: Bid & Secure Tender | Scenario B: Decline Bid / Sit Out |
|---|---|---|
| Volume Allocation | Secures 70%–80% of committed public hospital volume. | Reduced to competing for remaining 20%–30% uncommitted volume. |
| Margin Impact | Absolute gross profit per unit typically halves. Percentage gross margin falls far less (e.g. ~85% → ~73%), so the real damage lands on the operating line once fixed field-force cost is held constant. | Preserves high unit gross profit on limited private/out-of-pocket sales, but on a small and shrinking volume base. |
| Global Price Contagion | Risk of global reference pricing contagion if Chinese tender prices leak to Middle East/LATAM. | Protects global ASP (Average Selling Price) reference points. |
| Commercial Field Force | Requires immediate conversion from direct/distributor sales to lean Contract Sales Organizations (CSOs). | Requires downsizing sales reps or shifting field force to un-tendered portfolio. |
| Market Share & Defense | Defends overall market share against domestic competitors. | Concedes public hospital market share to domestic players (e.g., Mindray, Lepu, Weigao). |
The Premium Next-Generation Pivot Strategy
To survive VBP, leading multinationals employ the Next-Generation Pivot:
- Concede Legacy Portfolio to VBP: Submit competitive bids on legacy, mature product lines (e.g., first-generation drug-eluting stents or standard metallic hip stems) to capture baseline volume and maintain factory throughput.
- Accelerate NMPA Approval of Premium Technologies: Utilize fast-track registration pathways to introduce next-generation technologies (e.g., bioresorbable scaffolds, robotic-assisted surgical constructs, or quadripolar CRT-D leads) that fall outside the explicit technical specifications of active VBP tenders.
- Establish Dual-Brand / Dual-Entity Models: Form local joint ventures or sub-brands within China to bid domestic-tier products in VBP, while maintaining the primary multinational brand for premium private-market channels.
Cross-examine these market entry strategies against our analysis of top medical device companies 2026 revenue rankings and contrast state-managed VBP against US private payer dynamics in our guide to commercial insurance coverage for devices.
Frequently Asked Questions (FAQ)
Does VBP cover drugs, devices, or both?
VBP covers both pharmaceuticals and medical devices in China, but under separate administrative structures and on separate schedules. Pharmaceutical VBP (known as Guojia Ji Cai) began with the 2018 "4+7" city pilot and, as of July 2026, has completed eleven national batches covering 490 drugs — the eleventh produced results on October 27, 2025 and reached patients from February–March 2026. Medical device VBP began in 2020 under the National High-Value Consumables Joint Procurement Organisation and has completed six national batches covering 9 categories and 142 varieties. Device VBP involves far more complex product grouping because of structural, material, and sizing variation that does not exist in small-molecule generics — which is why device rounds use product-system grouping and comparison coefficients rather than the simple generic-name competition used for drugs.
What happens to a manufacturer that does not win or does not bid?
A manufacturer that does not win or declines to bid is excluded from the guaranteed 70% to 80% public hospital volume quota. Public hospitals are legally permitted to procure non-winning products only within the remaining 20% to 30% uncommitted quota. In practice, public hospital procurement committees face heavy administrative disincentives against buying non-tendered products, causing non-winning suppliers to lose 80%+ of their public hospital sales volume in affected provinces.
Can a company escape VBP by launching a next-generation premium device?
Temporarily, and less completely than it used to. VBP tender scope is defined by NHSA consumable code segments, so a device with a genuinely distinct clinical mechanism that earns its own generic name and classification does fall outside an active tender. But as next-generation technologies achieve adoption, NHSA routinely creates new VBP categories to capture them, historically within about 2 to 4 years.
The more important recent change is that NHSA has stopped treating "innovative" and "tendered" as mutually exclusive. Since Batch 5 (December 2024) it applies comparison coefficients that permit a more capable product to win at a proportionally higher price — cochlear implants were priced at a 1 : 1.2 : 1.3 ratio for no-MRI, 1.5T-compatible and 3.0T-compatible implants. Batch 6 extended the same logic to "micro-innovation" differences in drug-coated balloons and urological devices, and added a floor rule so an outlier low bid cannot drag a whole group down: when the lowest bid is abnormally low, the price-gap benchmark becomes 65% of the shortlisted average. Eight of twenty competition groups triggered it.
So the realistic strategy is no longer "stay outside the tender forever." It is: stay outside long enough to establish clinical preference and a premium price anchor, then enter the tender in the higher coefficient tier rather than the commodity tier.
How has VBP altered distributor commissions and CSO models in China?
Prior to VBP, medical device distributors in China commanded 50% to 300% gross markups to cover multi-tiered sales channels, hospital listing fees, and clinical support. VBP eliminated distributor markups by setting direct hospital purchase prices. As a result, traditional multi-tiered distributors have been replaced by Contract Sales Organizations (CSOs) operating on flat, low-percentage service fees (typically 5% to 12%) strictly for logistics, warehousing, and compliant in-service clinical training.
Primary Source & Verification References
- National Healthcare Security Administration (NHSA / 国家医疗保障局): Official centralized procurement policy directives and tender results. NHSA Official Portal. Batch 5 result announcement (cochlear implants and peripheral vascular stents, December 19, 2024): NHSA news release. Eleventh national drug batch result announcement (October 28, 2025): NHSA news release.
- NHSA coding standard (医保发〔2019〕39号): Rules and methods for the four medical insurance information codes — defines the consumable code structure (identifier, classification, generic name, product feature, manufacturer). NHSA code portal.
- Office of the US Trade Representative: 2023 China WTO Compliance Report written comments — official US government record of the national stent (>90%), joint (82%) and spinal (84%) price cuts and the 60–90% range for sub-national tenders. regulations.gov.
- Fujian Provincial Healthcare Security Bureau (福建省医疗保障局): Cardiac electrophysiology inter-provincial alliance procurement document and results (27 participating regions; 49.35% average reduction). Fujian HSB.
- Henan Provincial Healthcare Security Bureau (河南省医保局): Twelve-region orthopedic trauma alliance results, July 2021 (88.65% average reduction). Dahe News report.
- Anhui Provincial Medicine Price and Centralized Procurement Centre (安徽省医药价格和集中采购中心): 25-region inter-provincial IVD reagent alliance results (53.9% average, 73% maximum). Anhui procurement centre.
- Tianjin Medical Products Procurement Center (National JPO Host / 天津市医药采购中心): National high-value consumable joint bidding documents. TJMPC Tender Portal.
- ZS Associates Medtech Insight: How Volume-Based Procurement is Redefining Medtech Go-to-Market in China. ZS Medtech Insights. (Consultancy analysis, not an official source.)
- L.E.K. Consulting Executive Report: Navigating Medtech Volume-Based Procurement in China. L.E.K. Insights. (Consultancy analysis.)
- KPMG China Healthcare Advisory: Coping with Volume-Based Procurement on High-Value Medical Devices. KPMG China. (Consultancy analysis.)
- BMC Public Health (2026): The impact of centralized volume-based procurement policy on dental implant procurement volume — peer-reviewed record of the 55% average dental implant reduction and the 4,500 RMB implantation service cap. Springer.
- PubMed Central (PMC10577736): The National Volume-Based Procurement Policy in China: Impact on Device Innovation and Market Structure. PMC Article.
Source-type note: national and alliance round dates, participant counts, and average price reductions above are drawn from NHSA, provincial healthcare security bureau, and official government announcements, corroborated where noted by the USTR compliance report and peer-reviewed literature. Consultancy figures are labelled as such. The P&L illustration is MedDeviceGuide analysis. Currency conversions are approximate and referenced to mid-2026 rates.